Beijing Tiantan Biological Products Co., Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year

The third-quarter results for Beijing Tiantan Biological Products Co., Ltd. (SHSE:600161) were released last week, making it a good time to revisit its performance. It was a curious result overall, with revenues coming in an incredible 23% below what the analysts had expected, at CN¥1.2b. Statutory earnings per share beat analyst models by 91% to hit CN¥0.16. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.

View our latest analysis for Beijing Tiantan Biological Products

Taking into account the latest results, the most recent consensus for Beijing Tiantan Biological Products from ten analysts is for revenues of CN¥7.13b in 2025. If met, it would imply a substantial 36% increase on its revenue over the past 12 months. Statutory earnings per share are predicted to jump 28% to CN¥0.82. In the lead-up to this report, the analysts had been modelling revenues of CN¥7.21b and earnings per share (EPS) of CN¥0.83 in 2025. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results.

It will come as no surprise then, to learn that the consensus price target is largely unchanged at CN¥29.51. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. There are some variant perceptions on Beijing Tiantan Biological Products, with the most bullish analyst valuing it at CN¥31.60 and the most bearish at CN¥26.43 per share. The narrow spread of estimates could suggest that the business' future is relatively easy to value, or thatthe analysts have a strong view on its prospects.

One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. It's clear from the latest estimates that Beijing Tiantan Biological Products' rate of growth is expected to accelerate meaningfully, with the forecast 28% annualised revenue growth to the end of 2025 noticeably faster than its historical growth of 11% p.a. over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 26% annually. Beijing Tiantan Biological Products is expected to grow at about the same rate as its industry, so it's not clear that we can draw any conclusions from its growth relative to competitors.

The Bottom Line

The most important thing to take away is that there's been no major change in sentiment, with the analysts reconfirming that the business is performing in line with their previous earnings per share estimates. They also reconfirmed their revenue estimates, with the company predicted to grow at about the same rate as the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have estimates - from multiple Beijing Tiantan Biological Products analysts - going out to 2026, and you can see them free on our platform here.

We don't want to rain on the parade too much, but we did also find 1 warning sign for Beijing Tiantan Biological Products that you need to be mindful of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.